abstract |
The present invention relates to combination therapies comprising administration of: (1) a bispecific molecule capable of specifically binding to CD19 and binding to CD3 (ie, a CD19 x CD3 bispecific molecule), and (2) for treatment A disease, particularly a Bruton's tyrosine kinase (BTK) inhibitor that treats a disease associated with or characterized by expression of CD19. Preferably, such a CD19 x CD3 bispecific molecule is a bispecific monovalent diabodies. The present invention relates to a pharmaceutical composition comprising such a CD19 x CD3 bispecific molecule, a BTK inhibitor or a combination of these agents. The invention further relates to a method of treating a disease, in particular a cancer associated with or characterized by expression of CD19, using such a pharmaceutical composition. |